Skip to search formSkip to main contentSkip to account menu

CH 5132799

Known as: CH-5132799, CH5132799 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PyrimidinesSulfonamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Correction: First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
2013
2013
P06.08FINAL RESULTS OF PHASE I STUDY OF THE ORAL CLASS I PI3K INHIBITOR CH5132799 IN PATIENTS WITH ADVANCED SOLID TUMOURS
2012
2012
A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors.
3022 Background: The phosphatidylinositol 3-kinase (PI3K) pathway is a promising target in cancer. CH5132799 is a novel PI3K… 
2010
2010
122 Novel class I PI3K inhibitor CH5132799: potential clinical application in rational combination with molecular targeted therapeutics
2010
2010
108 Discovery of CH5132799, a novel class I PI3K inhibitor
2010
2010
74 Novel class I PI3K inhibitor CH5132799: disruption of the activated PI3K signaling in PIK3CA mutants confers potent antitumor efficacy
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)